Lead Sponsor

Arrowhead Pharmaceuticals

Age

19 - 65 years

Sex

ALL

Healthy Volunteers

Yes

•Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
•Willing to provide written informed consent and to comply with study requirements
•On a stable diet for at least 4 weeks with no plans to significantly alter diet or weight over course of study
•Normal electrocardiogram (ECG) at Screening
•No abnormal finding of clinical relevance (other than NASH, suspected NASH in patients) at Screening that could adversely impact subject safety during the study or adversely impact study results.

•Clinically significant health concerns (other than NASH, suspected NASH in patients)
•Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)
•Uncontrolled hypertension
•Excessive use of alcohol within three months prior to Screening
•Use of illicit drugs within 1 year prior to Screening, or positive urine drug screen at Screening
•Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
•\-
•\-

Related studies

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

NCT06819917 · Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and more

NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more

NCT03151473 · Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)

NCT06519448 · Non-alcoholic Steatohepatitis, Liver Diseases, and more

Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH